Rivaroxaban Extends Cancer P. E. Benefit Across P. S. 03/01/26
Welcome to Cardiology Today â Recorded March 01, 2026. This episode summarizes 5 key cardiology studies on topics like mycotic genitourinary infections and sodium glucose co-transporter two inhibitors. Key takeaway: Rivaroxaban Extends Cancer P. E. Benefit Across P. S..
Article Links:
Article 1: Long-term prognosis in Takotsubo Syndrome compared to Heart Failure: Observations from a global federated research network. (ESC heart failure)
Article 2: Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis. (European journal of heart failure)
Article 3: Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS. (Journal of the American Heart Association)
Article 4: Extended Anticoagulation Therapy With Rivaroxaban for Cancer-Associated Low-Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial. (Journal of the American Heart Association)
Article 5: Effects of Cardiac Resynchronization Therapy on Cardiovascular and Noncardiovascular Hospitalization: A MADIT-CRT Long-Term Follow-Up. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/rivaroxaban-extends-cancer-p-e-benefit-across-p-s-03-01-26/
đ Featured Articles
Article 1: Long-term prognosis in Takotsubo Syndrome compared to Heart Failure: Observations from a global federated research network.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41761829
Summary: This retrospective observational study established a cohort of adult patients with Takotsubo syndrome and heart failure discharged between 2018 and 2022 to directly compare their long-term clinical outcomes. It characterized the three-year risks for all-cause death, major adverse cardiovascular events, and acute heart failure in these distinct patient populations. The findings provide a direct comparative analysis of long-term prognosis, which is crucial for differentiating patient management strategies. This data clarifies differential clinical trajectories and informs targeted therapeutic approaches for Takotsubo syndrome versus heart failure.
Article 2: Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41762689
Summary: The EMPEROR-Pooled analysis found a significant impact of genitourinary tract infections and mycotic genitourinary infections on outcomes in heart failure patients, known to be associated with increased mortality risk. Results showed that sodium glucose co-transporter two inhibitors are associated with these types of infections, which often lead to treatment discontinuation. The analysis delineated the occurrence of genitourinary infections in both men and women with heart failure receiving sodium glucose co-transporter two inhibitors. This work provides essential evidence for clinicians to weigh the benefits and risks of sodium glucose co-transporter two inhibitors, guiding strategies to maintain treatment adherence.
Article 3: Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41757462
Summary: This retrospective analysis of 9752 patients with acute myocardial infarction treated with second-generation drug-eluting stents established that intravascular ultrasound-guided percutaneous coronary intervention improves patient outcomes. The study found that the prognostic association of intravascular ultrasound-guided percutaneous coronary intervention in acute myocardial infarction patients does differ based on a center’s level of intravascular ultrasound use. This outcome indicates that institutional experience with intravascular ultrasound is a critical factor influencing the long-term clinical benefits of this interventional approach. The data underscores the importance of high-volume centers or specialized training to maximize patient benefits from intravascular ultrasound-guided percutaneous coronary intervention.
Article 4: Extended Anticoagulation Therapy With Rivaroxaban for Cancer-Associated Low-Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41757461
Summary: The ONCO P. E. randomized trial definitively showed that 18-month rivaroxaban treatment was superior to 6-month treatment for reducing recurrent venous thromboembolism in patients with cancer-associated low-risk pulmonary embolism. This study analyzed the ONCO P. E. trial data and found that the benefits of extended 18-month rivaroxaban therapy for cancer-associated low-risk pulmonary embolism apply across patients with different performance status scores. The results demonstrate that performance status scores, which evaluate physical condition in cancer patients, do not diminish the efficacy of extended rivaroxaban. This ensures clinicians can confidently recommend the longer duration of rivaroxaban across a broader spectrum of cancer patients, optimizing recurrent venous thromboembolism prevention.
Article 5: Effects of Cardiac Resynchronization Therapy on Cardiovascular and Noncardiovascular Hospitalization: A MADIT-CRT Long-Term Follow-Up.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41757453
Summary: This long-term follow-up of the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy found that cardiac resynchronization therapy with defibrillation significantly impacts hospitalization patterns in heart failure patients. The analysis established differential effects of cardiac resynchronization therapy with defibrillation compared to implantable cardioverter-defibrillator on cardiovascular, heart failure, and noncardiovascular hospitalizations. Results showed changes in hospitalization rates and length of stay related to cardiac resynchronization therapy with defibrillation. These findings provide crucial long-term evidence for guiding device selection and optimizing patient management to reduce the burden of hospitalizations in heart failure.
đ Transcript
Today’s date is March 01, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Long-term prognosis in Takotsubo Syndrome compared to Heart Failure: Observations from a global federated research network. This retrospective observational study established a cohort of adult patients with Takotsubo syndrome and heart failure discharged between 2018 and 2022 to directly compare their long-term clinical outcomes. It characterized the three-year risks for all-cause death, major adverse cardiovascular events, and acute heart failure in these distinct patient populations. The findings provide a direct comparative analysis of long-term prognosis, which is crucial for differentiating patient management strategies. This data clarifies differential clinical trajectories and informs targeted therapeutic approaches for Takotsubo syndrome versus heart failure.
Article number two. Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis. The EMPEROR-Pooled analysis found a significant impact of genitourinary tract infections and mycotic genitourinary infections on outcomes in heart failure patients, known to be associated with increased mortality risk. Results showed that sodium glucose co-transporter two inhibitors are associated with these types of infections, which often lead to treatment discontinuation. The analysis delineated the occurrence of genitourinary infections in both men and women with heart failure receiving sodium glucose co-transporter two inhibitors. This work provides essential evidence for clinicians to weigh the benefits and risks of sodium glucose co-transporter two inhibitors, guiding strategies to maintain treatment adherence.
Article number three. Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS. This retrospective analysis of 9752 patients with acute myocardial infarction treated with second-generation drug-eluting stents established that intravascular ultrasound-guided percutaneous coronary intervention improves patient outcomes. The study found that the prognostic association of intravascular ultrasound-guided percutaneous coronary intervention in acute myocardial infarction patients does differ based on a center’s level of intravascular ultrasound use. This outcome indicates that institutional experience with intravascular ultrasound is a critical factor influencing the long-term clinical benefits of this interventional approach. The data underscores the importance of high-volume centers or specialized training to maximize patient benefits from intravascular ultrasound-guided percutaneous coronary intervention.
Article number four. Extended Anticoagulation Therapy With Rivaroxaban for Cancer-Associated Low-Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial. The ONCO P. E. randomized trial definitively showed that 18-month rivaroxaban treatment was superior to 6-month treatment for reducing recurrent venous thromboembolism in patients with cancer-associated low-risk pulmonary embolism. This study analyzed the ONCO P. E. trial data and found that the benefits of extended 18-month rivaroxaban therapy for cancer-associated low-risk pulmonary embolism apply across patients with different performance status scores. The results demonstrate that performance status scores, which evaluate physical condition in cancer patients, do not diminish the efficacy of extended rivaroxaban. This ensures clinicians can confidently recommend the longer duration of rivaroxaban across a broader spectrum of cancer patients, optimizing recurrent venous thromboembolism prevention.
Article number five. Effects of Cardiac Resynchronization Therapy on Cardiovascular and Noncardiovascular Hospitalization: A MADIT-CRT Long-Term Follow-Up. This long-term follow-up of the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy found that cardiac resynchronization therapy with defibrillation significantly impacts hospitalization patterns in heart failure patients. The analysis established differential effects of cardiac resynchronization therapy with defibrillation compared to implantable cardioverter-defibrillator on cardiovascular, heart failure, and noncardiovascular hospitalizations. Results showed changes in hospitalization rates and length of stay related to cardiac resynchronization therapy with defibrillation. These findings provide crucial long-term evidence for guiding device selection and optimizing patient management to reduce the burden of hospitalizations in heart failure.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
mycotic genitourinary infections, sodium glucose co-transporter two inhibitors, cardiac resynchronization therapy with defibrillation, rivaroxaban, implantable cardioverter-defibrillator, major adverse cardiovascular events, hospitalizations, genitourinary tract infections, treatment discontinuation, extended anticoagulation, institutional experience, venous thromboembolism, performance status, intravascular ultrasound, long-term prognosis, long-term follow-up, cancer-associated pulmonary embolism, heart failure, all-cause death, long-term outcomes, percutaneous coronary intervention, Takotsubo syndrome, acute myocardial infarction.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow